Nova Mentis (OTC: NMLSF) Receives Controlled Substances Export Approval From The U.S. DEA For The Company’s Proprietary Psilocybin Drug NM 1001
Vancouver, British Columbia– June 7, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory […]